Available from SPI Pharma
Orally disintegrating technology represents an advanced development—and growing trend—in pharmaceutical dosage forms, offering considerable advantages for life cycle management, development timelines, patient convenience and compliance, and market share.
SPI Pharma's innovative oral disintegrating technology platform, Pharmaburst® 500, has been successfully used in more than 60 marketed products worldwide. Global pharmaceutical manufacturers choose Pharmaburst ODT technology to formulate their drugs as oral disintegrating tablets because of its many benefits including:
Optimal compactibility with rapid disintegration for ODT tablets that are durable enough to withstand packaging and handling, yet meet the requirements for rapid disintegration (less than 30 seconds).
High component solubility, enabling the formulation of a fast-disintegrating ODT tablet even at high dosage levels (up to 500 mg).
Superior organoleptic properties, helping to ensure that each orally disintegrating tablet is palatable and provides a pleasant sensory experience.
Cost-effectiveness and accelerated speed to market for product line extensions and entry into new markets and patient populations.